| HOME >> MEDICINE >> TECHNOLOGY |
Patients Who Could Not Tolerate Dual-Antiplatelet Therapy
Michael Kutryk, M.D., Ph.D., of St. Michael's Hospital in Toronto discussed the results of a compassionate-use study that enrolled 14 patients who could not tolerate dual-antiplatelet therapy or for whom the therapy was contraindicated. The study results show no thrombotic events at 17-month median follow-up.
"The implantation of a Genous stent should be considered first-line therapy in patients for whom dual-antiplatelet therapy is not an option," said Kutryk. "The Genous technology is critically important to this patient population for which there are limited treatments. In these cases, Genous might be the only lifesaving option."
Single-Center Registry of High-Risk Patients
Germano Di Sciascio, M.D., professor and chairman of cardiology at
Campus Biomedico, University of Rome, discussed the results of a study
involving 78 high-risk patients, 33% of whom were diabetic. In the study,
16% of the patients received multiple stents, and 56% of the lesions
treated were type B2/C. The majority of patients received clopidogrel for
two months. The results at 14-month follow-up show:
-- A TLR rate of only 4%
-- An event-free survival rate of 84%
-- No thrombotic events
-- A comparable MACE rate to the Taxus VI registry at nine months
"Given the current DES debate with the need for prolonged anti-aggregation, we believe this study demonstrated that Genous is a new armamentarium for PCI," said Di Sciascio.
Commenting on the functional importance of endothelial progenitor cells
(EPCs) for accelerated natural healing, Jonathan Hill, M.D., of King's
College, London, said, "Interventional cardiologists are taking notice of
the critical role of EPCs in the vascular healing process. The Genous EPC
capture technology is
'/>"/>
| SOURCE OrbusNeich Copyright©2008 PR Newswire. All rights reserved |